In NSCLC, TGF-β signaling is frequently enhanced and promotes EMT and tumor metastasis, whereas SMAD3 inhibition diminished TGF-β-induced EMT in cancer cells [29]. This evidence concerns the gene SMAD3 and non-small cell lung carcinoma.